trial · primary record
CHF6333
Bronchiectasis
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 108 |
| Primary completion | 2026-08-27 |
| Primary endpoint | Safety and tolerability of single ascending doses of CHF6333 in HVs and a single dose in subjects with BE (Part I), and repeated doses in subjects with BE (Part II), in terms of AEs |
| Registry ID | NCT06166056 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:01.426Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06166056
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.